Alan vs Abridge

By valuation, Alan is the larger company at $1.4B versus $850M — a 1.6x difference. Size can also be measured by team: Alan employs 500-1000 people while Abridge has 120 employees.

Alan has raised more in total funding at $220M, compared to Abridge's $150M — a gap of $70M. Combined, the two companies have completed 5 known funding rounds.

Alan holds the higher Awaira Score at 83/100, compared to Abridge's 76/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 7-point gap that reflects meaningful differences in scale or traction.

Alan was founded by Jean-Charles Samuelian in 2016. Abridge was founded by Shiv Rao in 2018. Visit each company's profile on Awaira for a full founder biography.

Alan: Alan is an AI-powered health insurance platform that combines employer group health insurance products with a digital health companion application, using AI to personalise member health recommendations, streamline claims processing, and provide on-demand access to telehealth and mental health resources. The Paris company holds full insurance carrier status in France, Belgium, and Spain, operating as a licensed insurer rather than a distribution intermediary.\n\nThe company raised approximately $220 million including a Series D round from investors including Temasek, Coatue, and Index Ventures, reaching a valuation of approximately $1.4 billion. Alan reports over half a million members across its markets, covering employees at several thousand companies including Stripe, Spendesk, and Vinted, with strong growth in SME employer sales driven by its digital-first enrolment and claims experience. The Alan app provides members with health navigation, symptom checking, and AI-generated health content in addition to insurance card and claims management functionality.\n\nAlan competes in the European digital health insurance market against traditional mutuals including Malakoff Humanis and AG2R La Mondiale, as well as digital health insurers including Henner and Oscar Health in the US context. Its vertical integration as a licensed insurer combined with a technology platform differentiates it from insurtechs that distribute existing insurer products through digital channels, giving Alan full control over the member experience and claims economics. The company is considered one of the most significant French technology companies building in regulated financial services. Abridge: Abridge is an AI health company founded in 2018 that develops clinical documentation and conversation intelligence tools for healthcare providers. The company's core product uses artificial intelligence to automatically generate clinical notes from patient-physician conversations, addressing the administrative burden that consumes significant physician time. Abridge's technology leverages natural language processing and machine learning to transcribe, analyze, and summarize medical interactions, converting spoken dialogue into structured clinical documentation that integrates with existing electronic health record systems. The platform targets healthcare systems, hospitals, and outpatient practices seeking to reduce documentation workload and improve clinical efficiency. The company has secured $150M in total funding and maintains a valuation of $800M as of its Series B stage, reflecting investor confidence in the clinical AI documentation market. Abridge competes alongside other healthcare AI vendors addressing documentation automation, including companies focused on ambient clinical intelligence and voice-to-note solutions. The healthcare industry's ongoing digitization and physician burnout trends have created substantial demand for documentation automation tools. The company's growth trajectory reflects expanding adoption within healthcare systems seeking to improve provider productivity and patient interaction quality. Abridge's position in the AI health landscape centers on practical workflow optimization rather than diagnostic or treatment algorithms, targeting a specific high-value pain point in clinical operations. Abridge transforms clinical conversations into automated documentation, directly addressing physician administrative burden through ambient voice intelligence.

Alan was founded first in 2016, giving it 2 years of additional market experience. Abridge was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Alan has approximately 500-1000 employees, while Abridge has approximately 120. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Alan and Abridge are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.